Vortioxetine

Generic Name
Vortioxetine
Brand Names
Brintellix, Trintellix
Drug Type
Small Molecule
Chemical Formula
C18H22N2S
CAS Number
508233-74-7
Unique Ingredient Identifier
3O2K1S3WQV
Background

Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of se...

Indication

用于治疗重度抑郁症成人患者。

Associated Conditions
Major Depressive Disorder (MDD)
Associated Therapies
-
Clinical Trials
Related News

A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder

Phase 4
Completed
Conditions
Panic Disorder
Interventions
Drug: Vortioxetine
First Posted Date
2015-03-23
Last Posted Date
2016-07-25
Lead Sponsor
Siyan Clinical Corporation
Target Recruit Count
27
Registration Number
NCT02395510
Locations
🇺🇸

Siyan Clinical Corporation, Santa Rosa, California, United States

A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder

Phase 3
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
Drug: Vortioxetine
First Posted Date
2015-03-17
Last Posted Date
2021-03-24
Lead Sponsor
Takeda
Target Recruit Count
493
Registration Number
NCT02389816

Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)

Phase 4
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Vortioxetine
Drug: Placebo
First Posted Date
2015-02-26
Last Posted Date
2021-01-06
Lead Sponsor
Takeda
Target Recruit Count
1106
Registration Number
NCT02371980
Locations
🇺🇸

Atlanta Center for Medical Research, Atlanta, Georgia, United States

🇺🇸

Janice L. Miller, M.D., PA d/b/a Janus Center for Psychiatric Reseach, West Palm Beach, Florida, United States

🇺🇸

Collaborative Neuroscience Network, LLC, Torrance, California, United States

and more 71 locations

Adjunctive Vortioxetine in Schizophrenia

Phase 4
Active, not recruiting
Conditions
Schizophrenia
Negative Symptoms
Interventions
Drug: Vortioxetine
Other: Placebo
First Posted Date
2015-02-06
Last Posted Date
2024-02-08
Lead Sponsor
Northwell Health
Target Recruit Count
88
Registration Number
NCT02357797
Locations
🇺🇸

Cherry Health, Grand Rapids, Michigan, United States

🇺🇸

The Zucker Hillside Hospital, Glen Oaks, New York, United States

🇺🇸

Henderson Behavioral Health, Lauderdale Lakes, Florida, United States

Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine

Phase 4
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: vortioxetine
First Posted Date
2015-01-07
Last Posted Date
2018-01-30
Lead Sponsor
Lundbeck Canada Inc.
Target Recruit Count
226
Registration Number
NCT02332954
Locations
🇨🇦

CA029, Quebec, Canada

🇨🇦

CA013, Chatham, Ontario, Canada

🇨🇦

CA003, Mississauga, Ontario, Canada

and more 23 locations

Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder

First Posted Date
2014-11-19
Last Posted Date
2016-08-24
Lead Sponsor
The Medical Research Network
Target Recruit Count
40
Registration Number
NCT02294305
Locations
🇺🇸

The Medical Research Network, LLC, New York, New York, United States

Vortioxetine for Menopausal Depression

First Posted Date
2014-09-09
Last Posted Date
2017-06-28
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
47
Registration Number
NCT02234362
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

Phase 1
Completed
Conditions
Severe Hepatic Impairment
Interventions
Drug: Vortioxetine
First Posted Date
2014-06-23
Last Posted Date
2016-01-05
Lead Sponsor
Takeda
Target Recruit Count
12
Registration Number
NCT02170220
Locations
🇺🇸

University of Miami, Miami, Florida, United States

Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder

Phase 2
Completed
Conditions
Depressive Disorder
Anxiety Disorder
Interventions
Drug: Vortioxetine
First Posted Date
2011-12-13
Last Posted Date
2017-03-16
Lead Sponsor
H. Lundbeck A/S
Target Recruit Count
48
Registration Number
NCT01491035
Locations
🇺🇸

US004, Wichita, Kansas, United States

🇺🇸

US002, Cincinnatti, Ohio, United States

🇺🇸

US003, Washington, District of Columbia, United States

and more 4 locations

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

First Posted Date
2011-06-02
Last Posted Date
2014-10-09
Lead Sponsor
Takeda
Target Recruit Count
447
Registration Number
NCT01364649
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy